BioXcel Therapeutics, Inc. (BTAI)
BTAI moved a median of -0.75% 30 minutes after news, and -0.10% by the close. How BTAI actually reacts to news — the realized, point-in-time move the market made, measured across 392 labeled events over the last three years with zero look-ahead.
BTAI’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 48% | 391 |
| 30-min | -0.75% | 41% | 392 |
| 60-min | -0.36% | 42% | 392 |
| to close | -0.10% | 41% | 383 |
| Middle 50% of BTAI reactions | -2.97% to +1.28% |
|---|---|
| Median reaction (30-min) | -0.75% |
| Measured reactions | 392 |
Half of all BioXcel Therapeutics, Inc. news events land between -2.97% and +1.28% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BTAI reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 12 | +0.41% | 67% | +1.94% |
| Rating reiterations | 37 | +0.66% | 54% | +1.57% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how BTAI ranks against every other measured name →
That’s how BTAI usually reacts — get an email when it moves on news →Email me when BTAI moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BTAI's baseline. Nothing else.
Recent BTAI events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K BioXcel Therapeutics, For: Aug 31 | SEC filing · Form 8-K | SEC EDGAR | -5.79% | -2.14% | |
| BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals | Press release | GlobeNewswire | -2.54% | -14.52% | |
| Form 8-K BioXcel Therapeutics, For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | -2.54% | -14.52% | |
| Form 8-K BioXcel Therapeutics, For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | +2.15% | -5.20% | |
| Form 8-K BioXcel Therapeutics, For: Aug 21 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | -4.92% | |
| Form 10-Q BioXcel Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.91% | +7.21% | |
| Form 8-K BioXcel Therapeutics, For: Aug 10 | SEC filing · Form 8-K | SEC EDGAR | -1.67% | -3.44% | |
| Form 8-K BioXcel Therapeutics, For: Jul 31 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | +4.13% | |
| Form 8-K BioXcel Therapeutics, For: Jul 06 | SEC filing · Form 8-K | SEC EDGAR | -6.67% | -18.52% | |
| BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting | Press release | GlobeNewswire | -1.53% | -3.82% | |
| BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +1.28% | -2.56% | |
| Form 10-Q BioXcel Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.28% | -2.56% | |
| Form 8-K BioXcel Therapeutics, For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +1.28% | -2.56% | |
| Form 8-K BioXcel Therapeutics, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -3.28% | -5.74% | |
| BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting | Press release | GlobeNewswire | +0.31% | +4.54% | |
| Form 8-K BioXcel Therapeutics, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +3.13% | +7.14% | |
| Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? | Press release | PR Newswire | +2.78% | -1.85% | |
| BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions | Press release | GlobeNewswire | -0.87% | -4.35% | |
| BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting | Press release | GlobeNewswire | +1.09% | -10.95% | |
| Form 8-K BioXcel Therapeutics, For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +1.09% | -10.95% | |
| BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting | Press release | GlobeNewswire | -5.99% | -11.27% | |
| Form 10-K BioXcel Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.13% | -5.47% | |
| Form 8-K BioXcel Therapeutics, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | -5.99% | -11.27% | |
| Form S-8 BioXcel Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -3.13% | -5.47% | |
| BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering | Press release | GlobeNewswire | +0.64% | -1.27% | |
| Form 8-K BioXcel Therapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | -1.27% | |
| BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering | Press release | GlobeNewswire | +0.31% | -0.96% | |
| BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal | Press release | GlobeNewswire | -7.65% | -12.02% | |
| BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia | Press release | GlobeNewswire | -1.27% | +2.53% | |
| BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting | Press release | GlobeNewswire | -0.01% | -4.94% | |
| Form 8-K BioXcel Therapeutics, For: Feb 12 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -4.94% | |
| Form 8-K BioXcel Therapeutics, For: Feb 04 | SEC filing · Form 8-K | SEC EDGAR | -3.25% | +1.95% | |
| BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting | Press release | GlobeNewswire | +5.85% | +0.53% | |
| Form 8-K BioXcel Therapeutics, For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +5.85% | +0.53% | |
| Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | -0.68% | -2.97% | |
| BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting | Press release | GlobeNewswire | -1.74% | +0.50% | |
| Form 8-K BioXcel Therapeutics, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.74% | +0.50% | |
| BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI® | Press release | GlobeNewswire | +5.14% | +12.71% | |
| Form 8-K BioXcel Therapeutics, For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions | Press release | GlobeNewswire | -0.01% | +2.69% | |
| BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease | Press release | GlobeNewswire | +0.55% | -6.56% | |
| Form 10-Q BioXcel Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.55% | -6.56% | |
| Form 8-K BioXcel Therapeutics, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.55% | -6.56% | |
| Form ARS BioXcel Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.58% | — | |
| Form DEF 14A BioXcel Therapeutics, For: Dec 12 | SEC filing · Form DEF | SEC EDGAR | -0.58% | — | |
| Form 8-K BioXcel Therapeutics, For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | +2.12% | +2.66% | |
| Form PRE 14A BioXcel Therapeutics, For: Dec 12 | SEC filing · Form PRE | SEC EDGAR | -3.00% | -5.00% | |
| Form 8-K BioXcel Therapeutics, For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | -0.48% | -3.81% | |
| Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights | Press release | Business Wire | -0.39% | -1.23% | |
| BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes | Press release | GlobeNewswire | -3.06% | +0.38% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BTAI section they belong to.
Where else BTAI is measured.
BTAI earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| OHR PHARMACEUTICALS (OHRP) | 393 | 0.00% | 48% |
| ACADIA Pharmaceuticals Inc. (ACAD) | 392 | -0.14% | 43% |
| Karyopharm Therapeutics Inc. (KPTI) | 392 | -0.45% | 45% |
| Rubius Therapeutics, Inc. (RUBY) | 392 | -0.32% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BioXcel Therapeutics, Inc.'s median reaction calculated?
Every labeled BTAI news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 392 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of BTAI's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BTAI's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.